Humana Inc. HUM is positioned to benefit from increasing premium revenues, strategic acquisitions, an aging population in the United States and solid cash generation capacity. Headquartered in Louisville, KY, the company provides health insurance benefits through Health Maintenance Organization, Private Fee-For-Service and Preferred Provider Organization plans. It also provides specialty products such as dental, vision and other supplementary benefits.
Let’s delve deeper.
HUM’s Rising Premium Momentum
HUM continues to expand its membership base, particularly in the Medicare Advantage and state-based programs, which remain key growth engines. As of June 30, 2026, Group Medicare Advantage membership grew 27.6% year over year, while state-based contracts and other memberships rose 1.3%. Approximately 4.12 million members, representing 64% of individual Medicare Advantage membership, were engaged in value-based relationships through the company's integrated care delivery model. Humana’s premium revenues increased 10.7% in 2024, 9.6% in 2025 and 25% in the first half of 2026. Membership in state-based contracts is expected to increase by 25,000-100,000 in 2026, while individual Medicare Advantage membership is projected to grow around 25%.
HUM’s Segmental Performance & Growth Drivers
Humana is expanding its insurance business and healthcare services platform to support revenue growth. The company’s Insurance segment’s revenues increased 24.5% year over year in the first half of 2026. Improved per-member Medicare and stand-alone PDP premiums, coupled with an expanding customer base in Medicare businesses, are expected to support segment revenues. The segment’s revenues are forecasted at a minimum of $155 billion in 2026.
In the first half of 2026, the CenterWell segment’s revenues rose 21.2% year over year. Growth across primary care, pharmacy and home health services supported the segment’s performance. CenterWell Senior Primary Care added 130,900 patients year to date, up 27% from year-end 2025, reflecting continued expansion of its patient base. Continued patient additions and improved clinic productivity could support the segment’s longer-term growth. The company expects the CenterWell segment’s revenues to be at least $25 billion in 2026.
Humana's improving Medicare Advantage quality ratings also strengthen its growth prospects. In October 2026, the company announced that 95% of its Medicare Advantage members are enrolled in plans rated four stars or higher for 2027, potentially supporting higher quality-bonus payments and profitability in 2028.
Humana is pursuing growth through acquisitions, contract wins and strategic partnerships. In February 2026, CenterWell completed its acquisition of MaxHealth, a Florida-based primary care provider, to extend its reach in value-based care. Humana also secured a statewide Illinois Medicaid managed care contract scheduled to begin in January 2027. It also takes a disciplined approach to portfolio optimization by divesting non-core operations to enhance profitability. Additionally, Humana is leveraging technology, AI and automation to streamline operations, reduce administrative costs and improve service efficiency.
HUM’s Solid Financial Position
HUM’s solid financial position also provides flexibility to support growth and shareholder returns. As of June 30, 2026, the company had cash, cash equivalents and investment securities of $23.9 billion. HUM generated net cash from operations of $3.2 billion in the first half of 2026, which grew from $1.6 billion a year ago. The company continues to return capital through dividends and share repurchases. Humana repurchased common shares worth $108 million in the first half of 2026. It also paid dividends of $214 million in the first half of 2026.
HUM’s Impressive Earnings Surprise History
Humana boasts a robust earnings surprise record. It has topped estimates in each of the trailing four quarters, the average surprise being 9.6%.
Key Concerns
Despite its strengths, there are challenges to monitor. Humana has been witnessing increasing operating expenses for the past few years. In 2024, 2025 and the first half of 2026, the metric jumped 12.5%, 10.2% and 26.1% year over year, respectively. The consolidated benefit ratio deteriorated 180 basis points year over year to 90.2% in the first half of 2026. The company expects the Insurance segment benefit ratio to be 92.75%, with a variability margin of ±25 basis points, for 2026, indicating an increase from the 2025 level of 90.4%. Humana's substantial debt obligations and rising interest expenses also remain concerns.
How Are HUM’s Peers Performing?
Several competitors like Elevance Health, Inc. ELV and Centene Corporation CNC are also making moves.
Elevance Health is benefiting from higher premium yields and growth in CarelonRx. Operating revenues rose 1.2% year over year to $99.3 billion in the first half of 2026. However, elevated medical costs and declining government-sponsored membership remain challenges to ELV’s profitability and growth prospects.
Centene is making progress in restoring profitability through improved pricing and medical cost management. In the first six months of 2026, premium and service revenues increased 4.8% year over year to $89 billion. However, declining Medicaid and Marketplace membership remains a concern for CNC’s future growth.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Humana Inc. (HUM): Free Stock Analysis Report
Centene Corporation (CNC): Free Stock Analysis Report
Elevance Health, Inc. (ELV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).